Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

NCT02847403 · Unknown status

Last updated 2026-05-28

This clinical trial tested whether a long-acting version of the drug exenatide could slow cognitive decline in people with abnormal blood sugar levels and early signs of memory problems.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 51–79 · all sexes

Timeline Started 2016-02 · est. completion 2021-10

Where 2 sites · Italy

What this study is testing ClinicalTrials.gov NCT02847403 ↗

Description as written by the study sponsor.

The overall objective of the study is to assess the potential effects of the long-acting GLP-1 analogue exenatide in preventing/slowing the progression of cognitive dysfunction and related biomarkers in dysglycemic/prediabetic patients with mild cognitive impairment (MCI).

Treatments tested

Exenatide also known as bydureon Drug

Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
placebo Other

patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.

Main thing measured	Improvement of ADAS-cog Alzheimer's Disease Assessment Scale defined by ADAS-cog score at 16 (V2) and at 32 weeks (V3) compared to baseline
Sponsor	Azienda Ospedaliero-Universitaria di Parma
Conditions studied	Dysglycemia, Cognitive Deficit
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02847403 ↗